Details for New Drug Application (NDA): 020857
✉ Email this page to a colleague
The generic ingredient in COMBIVIR is lamivudine; zidovudine. There are twenty-nine drug master file entries for this compound. Eight suppliers are listed for this compound. Additional details are available on the lamivudine; zidovudine profile page.
Summary for 020857
| Tradename: | COMBIVIR |
| Applicant: | Viiv Hlthcare |
| Ingredient: | lamivudine; zidovudine |
| Patents: | 0 |
Pharmacology for NDA: 020857
| Mechanism of Action | Nucleoside Reverse Transcriptase Inhibitors |
Suppliers and Packaging for NDA: 020857
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| COMBIVIR | lamivudine; zidovudine | TABLET;ORAL | 020857 | NDA | ViiV Healthcare Company | 49702-202 | 49702-202-18 | 60 TABLET, FILM COATED in 1 BOTTLE (49702-202-18) |
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET;ORAL | Strength | 150MG;300MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | ||||
| Approval Date: | Sep 26, 1997 | TE: | RLD: | Yes | |||||
Expired US Patents for NDA 020857
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Viiv Hlthcare | COMBIVIR | lamivudine; zidovudine | TABLET;ORAL | 020857-001 | Sep 26, 1997 | ⤷ Get Started Free | ⤷ Get Started Free |
| Viiv Hlthcare | COMBIVIR | lamivudine; zidovudine | TABLET;ORAL | 020857-001 | Sep 26, 1997 | ⤷ Get Started Free | ⤷ Get Started Free |
| Viiv Hlthcare | COMBIVIR | lamivudine; zidovudine | TABLET;ORAL | 020857-001 | Sep 26, 1997 | ⤷ Get Started Free | ⤷ Get Started Free |
| Viiv Hlthcare | COMBIVIR | lamivudine; zidovudine | TABLET;ORAL | 020857-001 | Sep 26, 1997 | ⤷ Get Started Free | ⤷ Get Started Free |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Complete Access Available with Subscription
